Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Story summaryPharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion, the company said Wednesday.
Read at CNBCOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.